-
Innovation Ranking
Innovation Ranking – Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals Inc (Corvus Pharma) is a clinical-stage biopharmaceutical company. It is engaged in the development and commercialization of immuno-oncology therapies that are used for treating cancer. Corvus Pharma's product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in phase I clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine produced by the tumor cells. Corvus Pharma’s product pipeline...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986178 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986178 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986178 in Solid Tumor Drug Details: BMS-986178 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orca-Q in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orca-Q in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orca-Q in Acute Lymphocytic Leukemia (ALL,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orca-Q in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orca-Q in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orca-Q in Chronic Myelocytic Leukemia (CML,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ciforadenant in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ciforadenant in Sarcomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ciforadenant in Sarcomas Drug Details: Ciforadenant is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Soquelitinib in T-Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Soquelitinib in T-Cell Lymphomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Soquelitinib in T-Cell Lymphomas Drug Details: Soquelitinib (CPI-818) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Soquelitinib in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Soquelitinib in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Soquelitinib in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Soquelitinib in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Soquelitinib in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Soquelitinib in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Soquelitinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Soquelitinib in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Soquelitinib in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Soquelitinib in Atopic Dermatitis (Atopic Eczema) Drug Details: Soquelitinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ciforadenant in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ciforadenant in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ciforadenant in Colorectal Cancer Drug Details: Ciforadenant is under development for...